Cellerix is a product-focused biopharmaceutical company developing innovative medicines based on cell therapy. The Company is a recognized leader in the research and application of expanded autologous (patient-derived) and allogeneic (donor-derived) cells of adult origin in severe diseases with high unmet medical need.

Products:

Ontaril: a cell based therapy that uses adipose tissue as a source of stem cells, indicated for the treatment of complex perianal in Crohn's and non-Crohn's disease patients.

Cx501: a chimeric skin for the treatment of Recessive Distrophic Epidermolysis Bullosa (RDEB).

Cellerix is developing a new generation of products based on expanded allogeneic stem cells, derived from various donors (Cx601, Cx602 and Cx611, Cx621 programmes).

Web: www.cellerix.com